Categories: News

HMNC Brain Health to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MUNICH, Germany, Sept. 07, 2021 (GLOBE NEWSWIRE) — HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at the H.C. Wainwright 23rd Annual Global Investment Conference. HMNC Brain Health’s virtual presentation will be available beginning Monday, September 13th at 7:00am Eastern Time through Wednesday, September 15th and is accessible through the following webcast link: https://journey.ct.events/view/573f15f1-a6b8-4ae4-96e2-3a586b52b0b8.

In addition, HMNC Brain Health’s management team will participate in virtual one-on-one meetings throughout the day. To schedule a meeting or to request further information on the conference, please contact your H.C. Wainwright representative.

A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com 

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc@kcsa.com 

Investor Contact (U.S.)
Tim Regan / Rory Rumore
+1 347-487-6788
tregan@kcsa.com / rrumore@kcsa.com

Staff

Recent Posts

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

2 hours ago

CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech

BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…

2 hours ago

Therap Services Announces 2026 National Conference Schedule: Highlighting New Tools, Best Practices, and Over 250 Specialized Sessions

TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

2 hours ago

Catalyst by Wellstar Launches Polysight, Bringing Real-Time AI to Healthcare Compliance

The startup was formed to address rising regulatory complexity in healthcare.ATLANTA, Dec. 17, 2025 /PRNewswire/…

2 hours ago

Rockbridge Growth Equity-backed ProSites Acquires GeniusVets, Creating a Comprehensive Veterinary Marketing Platform under its LifeLearn Brand

LifeLearn offers a full suite of website creation, digital marketing, client communications and education, and…

2 hours ago

CORRECTION: TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care

PHILADELPHIA, PA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in…

2 hours ago